Brief: Unicycive Therapeutics Submits New Drug Application to FDA for Oxylanthanum Carbonate
03/09/2024 12:05
Sept 3 (Reuters) - Unicycive Therapeutics Inc UNCY.O :
* UNICYCIVE THERAPEUTICS ANNOUNCES SUBMISSION OF THE NEW
DRUG
APPLICATION (NDA) TO THE U.S. FDA FOR OXYLANTHANUM CARBONATE
(OLC) FOR THE TREATMENT OF HYPERPHOSPHATEMIA IN PATIENTS WITH
CHRONIC KIDNEY DISEASE ON DIALYSIS
* UNICYCIVE THERAPEUTICS INC - FDA GRANTS NDA PDUFA FEE
WAIVER TO
UNCYCIVE
Source text for Eikon: ID:nGNX4wh49s
Further company coverage: UNCY.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Unicycive Therapeutics
See all newsBrief: Unicycive Therapeutics Appoints Meredith Manning To Board Of Directors
Brief: Unicycive Therapeutics Announces Resubmission Of New Drug Application For Oxylanthanum Carbonate
U.S. RESEARCH ROUNDUP-Airbnb, Five Below, Silgan Holdings
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte, CoreWeave
Unicycive rises on narrower quarterly loss